Mucosal lesions in cutaneous lupus erythematosus successfully treated with hydroxychloroquine | Zendy

Kamaguchi Mayumi | Zendy; Iwata Hiroaki | Zendy; Asaka Takuya | Zendy; Shimizu Hiroshi | Zendy; Kitagawa Yoshimasa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Mucosal lesions in cutaneous lupus erythematosus successfully treated with hydroxychloroquine

Author(s) -

Kamaguchi Mayumi,

Iwata Hiroaki,

Asaka Takuya,

Shimizu Hiroshi,

Kitagawa Yoshimasa

Publication year - 2019

Publication title -

oral science international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.256

H-Index - 13

eISSN - 1881-4204

pISSN - 1348-8643

DOI - 10.1002/osi2.1006

Subject(s) - hydroxychloroquine , medicine , chloroquine , dermatology , cutaneous lupus erythematosus , systemic lupus erythematosus , autoimmune disease , lupus erythematosus , disease , immunology , pathology , malaria , covid-19 , infectious disease (medical specialty) , antibody

Cutaneous lupus erythematosus ( CLE ) is a rare, potentially disfiguring, chronic autoimmune disease with extremely variable skin and mucosal membrane manifestations. Hydroxychloroquine ( HCQ ) is an antimalarial drug that has been used in various countries to treat autoimmune diseases including CLE . HCQ was banned for a long time in Japan because of severe chloroquine retinopathy and was reapproved as a first‐line treatment for CLE in 2015. There are no case reports describing the effectiveness of HCQ for CLE with oral mucosal lesions in the dental field. We present a case of CLE whose oral lesions were successfully treated with HCQ .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research